Healthshape, an emerging startup from Lyon, combines regenerative medicine and technological innovation to offer women a new chance after a mastectomy due to breast cancer. Established in January 2020, the company quickly gained recognition for its innovative work on natural and resorbable breast bioprotheses, designed to integrate 3D printing technology. At the intersection of biotechnology and medical technology, Healthshape is redefining tissue reconstruction through a process that seems straight out of futuristic laboratories. With a solid portfolio of patents and extensive research, the company embodies innovative design in personalized and aesthetic medical solutions. Explore the biography of a company that continues to push boundaries and transform the future of health products through its expertise in R&D.
The roots of a health revolution: Healthshape and its origins
Emerging as a pioneer in the medtech field, Healthshape draws its roots from a flourishing academic and industrial ecosystem. By establishing itself in Lyon, a city recognized for its advancement in medical research and technology, Healthshape has taken root in particularly fertile ground. In January 2020, under the visionary impetus of Sophie Brac de la Perrière and her five co-founders, the company laid the groundwork for its bold project: developing personalized solutions for breast reconstruction through 3D printing.
This high-flying project revolves around a simple yet powerful principle: to use the patients’ own cells to promote tissue regeneration. This ambitious concept became a reality through a strategic collaboration with LabSkin Créations and the 3d.Fab platform. These chosen partners bring their respective expertise in tissue engineering and 3D printing, thus laying the foundation for cutting-edge medical technology.
| Partner | Expertise | Contribution to Healthshape |
|---|---|---|
| LabSkin Créations | Tissue engineering | Development of tissue models |
| 3d.Fab | 3D printing | Biomedical printing processes |
With the support of these collaborations, Healthshape has achieved significant results in the laboratory, proving the viability of its solutions. The challenges of Research and Development have been met efficiently, allowing the startup to rapidly project itself into a phase of industrialization. [See ni..Healshape for more information about this innovative company]
A revolutionary bioprothesis: technology at the service of women
Courage and innovation unite to form the core of Healthshape’s approach. Their flagship product, the breast bioprothesis, is not only a technical feat but also a profoundly humanistic solution. By using natural biomaterials printed in 3D, the company offers a prosthesis that harmoniously integrates into the patient’s tissues, resorbable and adaptable to each morphology.
The impact of this technology is immense, both medically and personally. For the first time, women who have undergone a mastectomy can consider a reconstruction that respects and utilizes their own biology to restore the natural appearance and feel of their breasts. This step towards more personalized and gentler medicine resonates with a global movement towards more individual-focused healthcare.
- A custom design thanks to 3D printing
- Use of biomaterials to minimize the risk of rejection
- Regeneration process assisted by body cells
The results speak for themselves: Healthshape’s bioprothesis not only promises to restore the volume and shape of the breast, but also encourages a sustainable regeneration of breast tissues. This health paradigm becomes accessible thanks to devices like those proposed in the Hexagon, visible through the recently raised funds
From the laboratory to clinics: the march towards industrialization
The transition from laboratory to clinical application is never easy. However, for Healthshape, the accumulating evidence is encouraging. The startup is now focusing on the industrialization of its creations, a crucial step that requires precision and rigor. This process relies on a key stage: optimizing processes to ensure large-scale production while meeting safety and efficacy standards.
This “scale-up” is supported by a robust funding strategy: in 2025, the company raised 6 million euros to intensify its efforts. These funds, essential for developing and refining production infrastructure, also reflect a growing confidence in Healthshape’s vision. The prospect of clinical trials on 15 patients represents a new phase of validation for these spectacular innovations. [Read more about the history of this funding in the full report]
| Stages | Objectives |
|---|---|
| Clinical trials | Evaluate efficacy and safety |
| Production optimization | Improve profitability and quality |
In co-incubation with Premières Auvergne-Rhône-Alpes, the company benefits from dynamic support to navigate this delicate phase. Pulsalys remains an unwavering ally, accompanying Healthshape both strategically and scientifically. For those interested, an insight into the driving forces behind this growth is available.
Support and partnerships: the cornerstone of Healthshape
The impact of Healthshape in the medtech field is not a solitary effort. The startup has surrounded itself with strategic partners to support its continuous development. Pule to stitch together the essential threads of innovative health networks in France, while seeking to pave the way for international recognition.
By benefiting from institutional support, Healthshape proves that with a clear vision and wise alliances, innovation in medical technology is not only possible, but also viable in the long term. These collaborations extend beyond national borders, aspiring to influence the global landscape of regenerative medicine.
- Incubation with PULSALYS and Premières AURA
- Partnership with university research units
- Cooperative research for improving industrial processes
This synergy embodies a crucial alliance between the academic and industrial sectors to advance health technologies, thereby enhancing the quality of life of patients globally. The unifying on the Pulsalys site treasures these collaborations that Healthshape has wisely embraced.
Visualizing the future: beyond biotechnology
The market for breast reconstruction sees Healthshape emerging as a key player that could reshape the future of the sector. This perspective hinges on a horizon of continuous innovations and an unwavering desire to overcome traditional medical obstacles. At Healthshape, innovation is not a destination; it is a perpetual journey towards perfection.
By exploring new biopolymers, refining 3D printing techniques, and conducting rigorous research in biotechnology, Healthshape is committed to expanding its scope. This determination promises to not only transform breast reconstruction but also inaugurate new therapeutic opportunities in other areas of healthcare.
The potential impact of these advances is already significant, with millions of women potentially benefiting from solutions that align with their individuality and respect their personal journey. Healthshape’s vision not only inspires the medical field but also invites a reevaluation of future technologies and care modalities to be integrated into the daily lives of healthcare institutions.
